{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:57:48Z","timestamp":1792277868885,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["Grant no. 175007\/contract No 451-03-47\/2023-01\/200111"],"award-info":[{"award-number":["Grant no. 175007\/contract No 451-03-47\/2023-01\/200111"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s13318-024-00887-3","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T13:01:38Z","timestamp":1709902898000},"page":"263-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Drug Interactions"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1519-8828","authenticated-orcid":false,"given":"Slobodan M.","family":"Jankovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sne\u017eana V.","family":"Jankovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"issue":"4","key":"887_CR1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","volume":"158","author":"S Iyengar","year":"2017","unstructured":"Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene\u2013related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158(4):543\u201359.","journal-title":"Pain"},{"issue":"4","key":"887_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/head.14103","volume":"61","author":"DC Buse","year":"2021","unstructured":"Buse DC, Armand CE, Charleston L IV, Reed ML, Fanning KM, Adams AM, et al. Barriers to care in episodic and chronic migraine: results from the chronic migraine epidemiology and outcomes study. Headache J Head Face Pain. 2021;61(4):628\u201341.","journal-title":"Headache J Head Face Pain."},{"issue":"4","key":"887_CR3","doi-asserted-by":"publisher","first-page":"033310242311593","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023;43(4):03331024231159366.","journal-title":"Cephalalgia"},{"key":"887_CR4","doi-asserted-by":"publisher","first-page":"251581632312073","DOI":"10.1177\/25158163231207322","volume":"6","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, Suzuki K, Shiina T, Haruyama Y, Hirata K. Evaluating the wearing-off effects of fremanezumab in high-frequency episodic migraine and chronic migraine: a real-world observational study in Japan. Cephalalgia Rep. 2023;6:25158163231207320.","journal-title":"Cephalalgia Rep."},{"issue":"20","key":"887_CR5","doi-asserted-by":"publisher","first-page":"e2121","DOI":"10.1212\/WNL.0000000000008944","volume":"94","author":"K Mullin","year":"2020","unstructured":"Mullin K, Kudrow D, Croop R, Lovegren M, Conway CM, Coric V, et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology. 2020;94(20):e2121\u20135.","journal-title":"Neurology"},{"issue":"8","key":"887_CR6","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/head.13930","volume":"60","author":"G Berman","year":"2020","unstructured":"Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, et al. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache. 2020;60(8):1734\u201342.","journal-title":"Headache"},{"issue":"4","key":"887_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/head.14095","volume":"61","author":"A Jakate","year":"2021","unstructured":"Jakate A, Blumenfeld AM, Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study. Headache. 2021;61(4):642\u201352.","journal-title":"Headache"},{"key":"887_CR8","unstructured":"Mueller L. Gepant efficacy when combined with a CGRP monoclonal antibody: a retrospective chart review. In: Headache. 111 River st, Hoboken 07030-5774, NJ USA: Wiley, 2021. p. 129."},{"key":"887_CR9","unstructured":"Freitag FG, Tolebeyan A, Sivakumar D. CGRP monoclonal antibodies along with CGRP receptor antagonists are safe and effective together and compared to standard of care. In: Headache. 111 River st, Hoboken 07030-5774, NJ USA: Wiley, 2021. p. 113."},{"issue":"9","key":"887_CR10","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/14740338.2022.2130890","volume":"21","author":"L Pellesi","year":"2022","unstructured":"Pellesi L. Combining two CGRP inhibitors to treat migraine. Expert Opin Drug Saf. 2022;21(9):1135\u20136.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"887_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15360288.2020.1829249","volume":"35","author":"M Armanious","year":"2021","unstructured":"Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. Erenumab and OnabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother. 2021;35(1):1\u20136.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"7","key":"887_CR12","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/head.13839","volume":"60","author":"SN Ozudogru","year":"2020","unstructured":"Ozudogru SN, Bartell JW, Yuan H, Digre KB, Baggaley SK. The effect of adding calcitonin gene-related peptide monoclonal antibodies to onabotulinum toxin A therapy on headache burden: a retrospective observational case series. Headache J Head Face Pain. 2020;60(7):1442\u20133.","journal-title":"Headache J Head Face Pain."},{"issue":"12","key":"887_CR13","first-page":"5373","volume":"42","author":"T Toni","year":"2021","unstructured":"Toni T, Tamanaha R, Newman B, Liang Y, Lee J, Carrazana E, et al. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2021;42(12):5373\u20136.","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol."},{"issue":"1","key":"887_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33425\/2639-846X.1037","volume":"4","author":"GP Boudreau","year":"2020","unstructured":"Boudreau GP. Treatment of chronic migraine with erenumab alone or as an add on therapy: a real-world observational study. Anesth Pain Res. 2020;4(1):1\u20134.","journal-title":"Anesth Pain Res"},{"issue":"2","key":"887_CR15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021;10(2):809\u201326.","journal-title":"Pain Ther"},{"issue":"8","key":"887_CR16","first-page":"1857","volume":"22","author":"F Cohen","year":"2021","unstructured":"Cohen F, Armand C, Lipton RB, Vollbracht S. Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to OnabotulinumtoxinA in patients with chronic migraine. Pain Med Malden Mass. 2021;22(8):1857\u201363.","journal-title":"Pain Med Malden Mass"},{"key":"887_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.656294","volume":"12","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A. Additive interaction between onabotulinumtoxin-A and Erenumab in patients with refractory migraine. Front Neurol. 2021;12: 656294.","journal-title":"Front Neurol"},{"key":"887_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107200","volume":"215","author":"AS Nandyala","year":"2022","unstructured":"Nandyala AS, Suri H, Dougherty CO, Ailani J. A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine. Clin Neurol Neurosurg. 2022;215: 107200.","journal-title":"Clin Neurol Neurosurg"},{"issue":"7","key":"887_CR19","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1111\/ene.14828","volume":"28","author":"A Alpuente","year":"2021","unstructured":"Alpuente A, Gallardo VJ, Caronna E, Torres-Ferr\u00fas M, Pozo-Rosich P. Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: a real-world evidence study. Eur J Neurol. 2021;28(7):2378\u201382.","journal-title":"Eur J Neurol"},{"issue":"12","key":"887_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/toxins14120847","volume":"14","author":"AA Argyriou","year":"2022","unstructured":"Argyriou AA, Dermitzakis EV, Xiromerisiou G, Vikelis M. OnabotulinumtoxinA add-on to monoclonal anti-CGRP antibodies in treatment-refractory chronic migraine. Toxins. 2022;14(12):847.","journal-title":"Toxins"},{"issue":"9","key":"887_CR21","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache. 2020;60(9):2014\u201325.","journal-title":"Headache"},{"issue":"1","key":"887_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/head.14244","volume":"62","author":"J Ailani","year":"2022","unstructured":"Ailani J, Blumenfeld AM. Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine. Headache. 2022;62(1):106\u20138.","journal-title":"Headache"},{"issue":"1","key":"887_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"I Frattale","year":"2021","unstructured":"Frattale I, Caponnetto V, Casalena A, Assetta M, Maddestra M, Marzoli F, et al. Association between response to triptans and response to erenumab: real-life data. J Headache Pain. 2021;22(1):1.","journal-title":"J Headache Pain"},{"issue":"10","key":"887_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.07.002","volume":"28","author":"S Aradi","year":"2019","unstructured":"Aradi S, Kaiser E, Cucchiara B. Ischemic stroke associated with calcitonin gene-related peptide inhibitor therapy for migraine: a case report. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2019;28(10): 104286.","journal-title":"J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc."},{"issue":"5","key":"887_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40263-019-00626-2","volume":"33","author":"Y Xu","year":"2019","unstructured":"Xu Y, Gabriel K, Wang Y, Zhou Y, Eisele O, Vutikullird A, et al. A multi-center, open-label, pharmacokinetic drug interaction study of erenumab and a combined oral contraceptive in healthy females. CNS Drugs. 2019;33(5):513\u201322.","journal-title":"CNS Drugs"},{"key":"887_CR26","doi-asserted-by":"crossref","unstructured":"Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug\u2013drug interactions of new anti-migraine drugs\u2014Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12(12):1180.","DOI":"10.3390\/pharmaceutics12121180"},{"issue":"1","key":"887_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12883-021-02294-6","volume":"21","author":"CK Cullum","year":"2021","unstructured":"Cullum CK, Olsen MK, Kocadag HB, Ashina M, Amin FM. Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: a case report. BMC Neurol. 2021;21(1):257.","journal-title":"BMC Neurol"},{"issue":"5","key":"887_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/head.13316","volume":"58","author":"C Depre","year":"2018","unstructured":"Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018;58(5):715\u201323.","journal-title":"Headache"},{"issue":"4","key":"887_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.7934","volume":"4","author":"ID Breen","year":"2021","unstructured":"Breen ID, Brumfiel CM, Patel MH, Butterfield RJ, VanderPluym JH, Griffing L, et al. Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw Open. 2021;4(4): e217934.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"887_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4625","volume":"9","author":"AH Manickam","year":"2021","unstructured":"Manickam AH, Buture A, Tomkins E, Ruttledge M. Raynaud\u2019s phenomenon secondary to erenumab in a patient with chronic migraine. Clin Case Rep. 2021;9(8): e04625.","journal-title":"Clin Case Rep."},{"issue":"8","key":"887_CR31","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/head.13596","volume":"59","author":"RW Evans","year":"2019","unstructured":"Evans RW. Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists. Headache J Head Face Pain. 2019;59(8):1360\u20134.","journal-title":"Headache J Head Face Pain."},{"issue":"13","key":"887_CR32","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia Int J Headache. 2020;40(13):1511\u201322.","journal-title":"Cephalalgia Int J Headache."},{"issue":"19","key":"887_CR33","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1212\/WNL.0000000000201332","volume":"99","author":"J Ailani","year":"2022","unstructured":"Ailani J, Kaiser EA, Mathew PG, McAllister P, Russo AF, V\u00e9lez C, et al. Role of calcitonin gene-related peptide on the gastrointestinal symptoms of migraine\u2014clinical considerations. Neurology. 2022;99(19):841\u201353.","journal-title":"Neurology"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00887-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00887-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00887-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T02:09:51Z","timestamp":1714183791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00887-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00887-3","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"assertion":[{"value":"26 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Partial financial support was received from the Ministry of Education, Science and Technological Development, Serbia, via Grant No. 175007\/contract no. 451-03-47\/2023-01\/200111.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors certify that they have no other relevant affiliations or financial involvement with any organization or entity with a financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable for review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable for review article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable for review article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable for review article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable for review article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Slobodan Jankovi\u0107 \u2013 concept of the review, literature search, quality assessment of retrieved articles, writing the manuscript, control of completed manuscript. Sne\u017eana Jankovi\u0107 \u2013 concept of the review, literature search, quality assessment of retrieved articles, writing the manuscript, control of completed manuscript","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}